As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Bristol-Myers Squibb Company in the Anxiety Disorder Treatment market. In 2023, the Anxiety Disorder Treatment market (不安障害治療薬 市場 ) was valued at US$ 11.8 Billion. The market is forecast to grow at a ...

Products that are based on market cap weighted indexes ... accounts for about 2.81% of the fund's total assets, followed by Bristol-Myers Squibb Co (BMY) and Gilead Sciences Inc (GILD).

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Before that, Alan had a 23-year career with Bristol-Myers Squibb, where he held various leadership positions across all major ...

Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

In our latest interview, AZoMaterials speaks with Strongwell about their new STRONGDEK™ structural composite decking system, ...